[go: up one dir, main page]

CA2166731A1 - Combinaisons d'antacide, d'alginate et d'antagoniste des recepteurs de h2 - Google Patents

Combinaisons d'antacide, d'alginate et d'antagoniste des recepteurs de h2

Info

Publication number
CA2166731A1
CA2166731A1 CA002166731A CA2166731A CA2166731A1 CA 2166731 A1 CA2166731 A1 CA 2166731A1 CA 002166731 A CA002166731 A CA 002166731A CA 2166731 A CA2166731 A CA 2166731A CA 2166731 A1 CA2166731 A1 CA 2166731A1
Authority
CA
Canada
Prior art keywords
relief
gastrointestinal
antacid
amount effective
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002166731A
Other languages
English (en)
Inventor
Robert T. Sims
William Slivka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenvue Brands LLC
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2166731A1 publication Critical patent/CA2166731A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)

Abstract

Cette invention concerne des compositions pharmaceutiques utilisables dans le traitement et le soulagement des indigestions, des aigreurs d'estomac, des brûlures d'estomac et des autres troubles gastro-intestinaux chez les mammifères, y compris l'homme. Ce traitement comprend l'administration de compositions comportant: (i) une quantité, efficace pour le soulagement des troubles gastro-intestinaux ou de l'oesophage, d'un antagoniste H2 sélectionné parmi un composé de la formule (I) et ses sels, hydrates, stéréo-isomères ou composés polymorphes pharmaceutiquement acceptables et (ii) une quantité, efficace pour le soulagement des troubles gastro-intestinaux ou de l'oesophage, d'au moins un alginate et (iii) une quantité, efficace pour le soulagement des embarras gastro-intestinaux, d'un antiacide procurant un effet régulateur et générant du dioxyde de carbone pour aérer l'alginate.
CA002166731A 1993-07-06 1994-07-05 Combinaisons d'antacide, d'alginate et d'antagoniste des recepteurs de h2 Abandoned CA2166731A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8793793A 1993-07-06 1993-07-06
US087,937 1993-07-06
PCT/US1994/007519 WO1995001795A1 (fr) 1993-07-06 1994-07-05 Combinaison antiacide-alginate-antagoniste h¿2?

Publications (1)

Publication Number Publication Date
CA2166731A1 true CA2166731A1 (fr) 1995-01-19

Family

ID=22208161

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002166731A Abandoned CA2166731A1 (fr) 1993-07-06 1994-07-05 Combinaisons d'antacide, d'alginate et d'antagoniste des recepteurs de h2

Country Status (5)

Country Link
EP (1) EP0707484A4 (fr)
JP (1) JPH08512321A (fr)
AU (1) AU7218194A (fr)
CA (1) CA2166731A1 (fr)
WO (1) WO1995001795A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
CA2251854A1 (fr) * 1996-05-02 1997-11-06 Carl Shellenberger (Deceased) Methode de prevention de troubles gastro-intestinaux
WO1998014198A1 (fr) * 1996-10-04 1998-04-09 Merck & Co., Inc. Procedes et compositions pour la prevention et le traitement des brulures d'estomac
WO1998023272A1 (fr) * 1996-11-27 1998-06-04 The Procter & Gamble Company Compositions et procedes pour le traitement de troubles gastro-intestinaux
AU1453600A (en) * 1998-11-04 2000-05-22 Mcneil-Ppc, Inc. Solid oral dosage forms containing alginic acid and famotidine
US6930119B2 (en) * 2002-07-17 2005-08-16 Reliant Pharmaceuticals, Inc. Liquid pharmaceutical composition
BRPI0621391A2 (pt) * 2006-03-09 2011-12-06 World Trade Imp Export Wtie Ag combinação sinérgica de inibidores de receptores h2, silicone inerte e um complexo de aluminato de hidroximagnésio
DE102006037298A1 (de) 2006-08-08 2008-02-14 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Pharmazeutische Zusammensetzung, insbesondere Antazidum
DE102008019339A1 (de) * 2008-04-16 2009-10-22 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die medizinische Anwendung, insbesondere Antazidum
US20180140630A1 (en) * 2016-11-23 2018-05-24 M. Michael Wolfe Combination of an h2-receptor antagonist, antacid, and alginic acid to treat episodic heartburn
IT201800002625A1 (it) 2018-02-13 2019-08-13 Drugs Minerals And Generics Italia S R L In Forma Abbreviata D M G Italia S R L Composizione in forma solida per uso nel trattamento dei sintomi extra-esofagei del reflusso gastrico
IT201800007771A1 (it) * 2018-08-02 2020-02-02 Drugs Minerals And Generics Italia Srl In Forma Abbreviata Dmg Italia Srl Combinazione per uso nel trattamento dei sintomi extra-esofagei del reflusso gastrico
IT202100029657A1 (it) * 2021-11-24 2023-05-24 Mauro Leonardis Sciroppo anti-reflusso sterile senza conservanti

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327748C (fr) * 1988-09-20 1994-03-15 Christopher William Quirk Composition pharmaceutique contenant de la ranitidine et de l'acide alginique
US5229137A (en) * 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
AU7218294A (en) * 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-alginate combinations

Also Published As

Publication number Publication date
EP0707484A1 (fr) 1996-04-24
JPH08512321A (ja) 1996-12-24
EP0707484A4 (fr) 1998-07-01
AU7218194A (en) 1995-02-06
WO1995001795A1 (fr) 1995-01-19

Similar Documents

Publication Publication Date Title
CA2166731A1 (fr) Combinaisons d'antacide, d'alginate et d'antagoniste des recepteurs de h2
US5538954A (en) Salts of tetracyclines
JP2013100334A (ja) 固体投与形中のテトラサイクリン金属錯体
JPH03181422A (ja) 炎症の治療方法及び炎症の治療用合成薬
JPH08512322A (ja) Ｈ▲下２▼拮抗剤−胃腸運動性の薬剤組合せ物
WO1995001780A1 (fr) Combinaisons alginate-antagoniste de h¿2?
ES2547379T3 (es) Utilización de calcitonina para el tratamiento de la AR
KR20010024050A (ko) 항균제
US3919291A (en) N-ethylcarbaminomethylisoleucine
WO1995001792A1 (fr) Composes anti-h2-antihistaminiques
EP0551180B1 (fr) Utilisation de bucillamine pour la fabrication d'un médicament pour le traitement de la cystinurie
CN114432425B (zh) 一种多肽在预防和治疗胃部疾病的药物中的应用
RU2217158C1 (ru) Способ профилактики и лечения язв желудка у животных
CN108992456B (zh) 含有香叶木苷硫酸酯衍生物的药物组合物及其应用
WO1995001784A1 (fr) Composes anti-flatulences a base d'antagoniste d'h2 et de sucralfate
CN101259141A (zh) 一种复方海藻酸咀嚼片及其制备方法
WO1995003799A1 (fr) Utilisation de la benzydamine dans le traitement d'etats pathologiques dus au facteur de necrose tumorale
US5135925A (en) Use of zinc acexamate in the prophylaxis of gastropathy induced by non-steroidal anti-inflammatory drugs
JP2900056B2 (ja) 非ステロイド抗炎症剤により生じる胃疾患の予防用医薬組成物
EA007863B1 (ru) Применение дистронциевой соли 2-[n,n-ди(карбоксиметил)амино]-3-циано-4-карбоксиметилтиофен-5-карбоновой кислоты при получении лекарственных средств, предназначенных для лечения гастродуоденальной боли
RU2002104753A (ru) Способ профилактики и лечения лейкоза крупного рогатого скота
CN1572309A (zh) 一种中药新制剂乌贝干混悬剂及其制备方法
JP2898930B2 (ja) 消化器症状改善剤
RU1831338C (ru) Средство, обладающее противо звенной активностью
JP2004331660A (ja) 医薬組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead